276 results on '"Armstrong, Paul W."'
Search Results
2. Evolution of NT-proBNP During Prerandomization Screening in VICTORIA: Implications for Clinical Outcomes and Efficacy of Vericiguat
3. Background Medical Therapy and Clinical Outcomes From the VICTORIA Trial
4. STREAM-2: Half-Dose Tenecteplase or Primary Percutaneous Coronary Intervention in Older Patients With ST-Segment–Elevation Myocardial Infarction: A Randomized, Open-Label Trial
5. STREAM-2: Half-Dose Tenecteplase or Primary Percutaneous Coronary Intervention in Older Patients With ST-Segment–Elevation Myocardial Infarction: A Randomized, Open-Label Trial
6. Clinical Implications of Negatively Adjudicated Heart Failure Events: Data From the VICTORIA Study
7. Abstract 11603: Comparing Analytical Methods for Composite Endpoints in Heart Failure With Reduced Ejection Fraction: Insights From the VICTORIA Trial
8. Abstract 11574: Relationship Between Baseline Electrocardiographic Parameters and Outcomes in Patients With High-Risk Heart Failure With Reduced Ejection Fraction: Insights From the Vericiguat Global Study in Patients With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial
9. Abstract 11453: Age, Sex, and Outcomes in Heart Failure With Reduced Ejection Fraction: Insights From the VICTORIA Trial
10. Hemoglobin and Clinical Outcomes in the Vericiguat Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA)
11. Extending the Product Label for Ticagrelor: Looking Under the FDA Hood
12. Abstract 15589: Mitochondrial Metabolites Predict Cardiovascular Outcomes and Heart Failure in People With Type 2 Diabetes Mellitus and Vascular Disease: A Tecos Substudy
13. Abstract 14727: Meteorin-like Glial Cell Differentiation Regulator is a Novel Protein Biomarker of Cardiovascular Outcomes in Patients With Diabetes and Vascular Disease: A TECOS Substudy
14. Abstract 13829: Index Event, Clinical Outcomes and Response to Vericiguat in the Victoria Trial
15. Long-Term Bleeding Risk Prediction with Dual Antiplatelet Therapy After Acute Coronary Syndromes Treated Without Revascularization
16. Comparing the Benefit of Novel Therapies Across Clinical Trials: Insights From the VICTORIA Trial
17. ST-Segment–Elevation Myocardial Infarction Care and COVID-19: The Value Proposition of Fibrinolytic Therapy and the Pharmacoinvasive Strategy
18. Pharmacoinvasive Strategy Versus Primary Percutaneous Coronary Intervention in ST-Elevation Myocardial Infarction in Clinical Practice: Insights From the Vital Heart Response Registry
19. Rationale and Design of the VITALITY-HFpEF Trial
20. Prevention of Cardiogenic Shock After Acute Myocardial Infarction
21. Days Alive and Out of Hospital: Exploring a Patient-Centered, Pragmatic Outcome in a Clinical Trial of Patients With Acute Coronary Syndromes
22. Relationship Between Enrolling Country Income Level and Patient Profile, Protocol Completion, and Trial End Points: From the ASCEND-HF Trial
23. Early discontinuation of prasugrel or clopidogrel in acute coronary syndromes: insights from the TRILOGY ACS trial
24. Circulation Global Rounds
25. Exploring New Cardiovascular Pathways: Are Soluble Guanylate Cyclase Stimulators the Right Direction?
26. Aetiology, timing and clinical predictors of early vs. late readmission following index hospitalization for acute heart failure: insights from ASCEND‐HF
27. Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial
28. Abstract 16058: Country Income Level, Protocol Completion, and Trial Endpoints Among Patients With Acute Heart Failure: Insights From the ASCEND-HF Trial
29. Hypertension Control in Adults With Diabetes Mellitus and Recurrent Cardiovascular Events: Global Results From the Trial Evaluating Cardiovascular Outcomes With Sitagliptin
30. Relationships Between Baseline Q Waves, Time From Symptom Onset, and Clinical Outcomes in ST-Segment–Elevation Myocardial Infarction Patients: Insights From the Vital Heart Response Registry
31. Does renal function affect the efficacy or safety of a pharmacoinvasive strategy in patients with ST-elevation myocardial infarction? A meta-analysis
32. Recalibrating Reperfusion Waypoints
33. Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus: International Insights From the TECOS Trial (Trial Evaluating Cardiovascular Outcomes With Sitagliptin)
34. Insufficient reduction in heart rate during hospitalization despite beta‐blocker treatment in acute decompensated heart failure: insights from the ASCEND‐HF trial
35. Corrigendum to “Reduced dose tenecteplase and outcomes in elderly ST-segment elevation myocardial infarction patients: Insights from the Strategic Reperfusion Early After Myocardial infarction trial” [Am Heart J 169/6 (2015) 890–898]
36. Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS trial
37. Diabetes and heart failure in the crosshairs: where is the target?
38. Time-Varying Effects of Prasugrel Versus Clopidogrel on the Long-Term Risks of Stroke After Acute Coronary Syndromes: Results From the TRILOGY ACS Trial
39. Liver function tests in patients with acute heart failure and associated outcomes: insights from ASCEND-HF
40. Implications of ischaemic area at risk and mode of reperfusion in ST-elevation myocardial infarction
41. Renal failure in patients with ST-segment elevation acute myocardial infarction treated with primary percutaneous coronary intervention: Predictors, clinical and angiographic features, and outcomes
42. Increased mortality with elevated plasma endothelin-1 in acute heart failure: an ASCEND-HF biomarker substudy
43. The clinical course of health status and association with outcomes in patients hospitalized for heart failure: insights from ASCEND-HF
44. Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome
45. High-degree atrioventricular block, asystole, and electro-mechanical dissociation complicating non–ST-segment elevation myocardial infarction
46. Worsening heart failure during hospitalization for acute heart failure: Insights from the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF)
47. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
48. The Effects of Climate Change on Cardiac Health
49. The future of cardiovascular clinical research in North America and beyond—addressing challenges and leveraging opportunities through unique academic and grassroots collaborations
50. Impact of a pharmacoinvasive strategy when delays to primary PCI are prolonged
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.